Related Experiment Videos
The extended pharmaceutical enterprise
1Arachnova, St John's Innovation Centre, Cambridge, UK CB4 0WS. david.cavalla@arachnova.com
Drug Discovery Today
|March 8, 2003
Summary
The rise of virtual companies, enabled by contractual services, has transformed pharmaceutical R&D. Intellectual property exchange through collaborations and licensing further expands outsourced research opportunities.
Area of Science:
- Biotechnology
- Pharmaceutical Sciences
- Business Management
Background:
- The 1990s saw the emergence of virtual companies driven by accessible contractual services.
- The biotechnology sector has experienced significant diversification and growth.
- Outsourcing has become a key strategy in pharmaceutical research and development.
Purpose of the Study:
- To analyze the evolution and impact of virtual companies in pharmaceutical R&D.
- To explore the role of intellectual property exchange in facilitating outsourced R&D.
- To understand how collaborative and licensing arrangements enhance R&D opportunities.
Main Methods:
- Conceptual analysis of industry trends.
- Review of business models in biotechnology and pharmaceutical sectors.
- Examination of intellectual property management strategies.
Main Results:
- Widespread contractual services facilitated the creation of virtual companies.
- Maturation of the virtual company concept has paralleled biotechnology sector diversification.
- Intellectual property interchange via collaborations and licenses expands outsourced R&D.
Conclusions:
- Virtual companies, enabled by contractual services, represent a significant shift in pharmaceutical R&D.
- Collaborative and licensing agreements are crucial for leveraging intellectual property in outsourced R&D.
- The model of outsourced pharmaceutical R&D continues to evolve, offering expanded opportunities.